- Home
- PSNL vs CNTB Comparison
PSNL vs CNTB Comparison
Compare PSNL & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | CNTB |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 128.6M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PSNL | CNTB |
|---|---|---|
| Price | $8.42 | $2.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $10.71 | $8.50 |
| AVG Volume (30 Days) | ★ 1.7M | 298.5K |
| Earning Date | 11-04-2025 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,103,000.00 | $762,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.33 | $38,289.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.83 | $0.51 |
| 52 Week High | $11.40 | $3.28 |
Technical Indicators
Market Signals| Indicator | PSNL | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 45.71 | 56.97 |
| Support Level | $7.68 | $2.11 |
| Resistance Level | $9.10 | $2.65 |
| Average True Range (ATR) | 0.58 | 0.19 |
| MACD | -0.15 | -0.03 |
| Stochastic Oscillator | 26.06 | 82.26 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.